OpenResearchAlpha

Annals of Surgery · 17 Nov 2026

Ex Vivo Lung Perfusion and Allograft Failure After Lung Transplantation

Sara Sakowitz, Syed Shahyan Bakhtiyar, Yas Sanaiha, Deep Mehta, Richard J. Shemin, Peyman Benharashh-index 17

0
Citations
no database records one yet
0
Citations in 2026
so far
17
Leading author's h-index
Peyman Benharash, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Objective: Ex vivo lung perfusion (EVLP) has been championed as a disruptive strategy to expand the lung transplantation (LT) donor pool, yet contemporary evidence remains limited. Using a real-world cohort, we emulated a randomized controlled trial (RCT) to characterize the causal effect of EVLP on post-LT survival. Methods: LT recipients ≥18 years were identified from the 2018–2025 Organ Procurement and Transplantation Network. Annual hospital LT volume was computed; centers in the top quartile (>54 LT/y) were designated high-volume centers (HVCs). Using target trial emulation with clone-censor-weight methodology, we simulated a pragmatic, open-label RCT comparing EVLP with standard allografts at HVCs and non-HVCs. Survival was evaluated using Kaplan-Meier and multivariable Cox models. Results: Among 20,627 LTs, 1419 (7%) received EVLP allografts. The proportion of EVLP allografts increased across all centers, from 5% in 2018 to 10% in 2024 and 8% in 2025 ( P trend <0.001). In the Lung Allocation Score era, LT using EVLP allografts yielded similar 2-year outcomes at HVC, but inferior outcomes at non-HVC. In the Composite Allocation Score period, however, EVLP was associated with significantly worse survival at non-HVC. In the emulated RCT among CAS-era recipients, EVLP remained independently associated with similar outcomes at HVC, but increased 2-year hazards of patient mortality (HR: 2.43, CI: 1.36–4.34, P =0.003) and allograft failure at non-HVC (HR: 2.52, CI: 1.31–4.84, P =0.005). Conclusions: EVLP was associated with comparable survival at HVC but inferior outcomes at non-HVC. These findings highlight the critical role of hospital context and center experience in determining the effectiveness and safety of EVLP and call for standardization of protocols across centers.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Peyman Benharash has the highest h-index among the authors (17).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (6)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.